VANCOUVER, Feb. 22, 2019 /CNW/ - Dexcom, Inc.
(NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM),
today announced that the company has received Health Canada
approval for its next generation Dexcom G6 CGM System for people
with diabetes ages two years and up.
This approval now clears the way for the Dexcom G6 to be made
available to Canadians with diabetes. It was previously introduced
into the U.S, U.K., Ireland, and
several other European countries and has seen strong sales.
The G6 commercial launch in Canada
is planned for late 2019 as the company continues to build capacity
to support global launch plans.
"The Dexcom G6 represents another step forward in diabetes
management," said Paul Flynn, Vice
President, Dexcom Canada, Inc. "This next generation product
continues the performance, features, and accuracy that the diabetes
community has come to expect from Dexcom CGM. We're proud and
excited to be able to bring it to Canadians this year, once we're
in a position to reliably meet demand."
The G6 has a new transmitter, a new sensor with new
auto-applicator, and a new touchscreen receiver (which is an
optional display device for Dexcom CGM). These new components share
and build upon the core attributes of the currently available
Dexcom G5 Mobile CGM technology platform:
- No fingersticks for diabetes treatment decisions*
- Continuous glucose readings sent automatically to any
compatible smart device† (or a Dexcom receiver), using Bluetooth
technology
- Customizable alerts and alarms to warn users of dangerous
glucose levels, even while they are asleep – a particularly useful
feature for those with glucose variability and impaired
hypoglycemia awareness
- Real-time data sharing with up to five Followers‡,
allowing authorized others to view the user's glucose levels
remotely
More information about Dexcom and how to get started with
continuous glucose monitoring can be found at www.dexcom.com.
About Dexcom G5 Mobile & Dexcom G6 CGM Systems
The
Dexcom G5 Mobile and Dexcom G6 are stand-alone CGM systems for
people with diabetes on multiple daily injection therapy (primarily
the Type 1 diabetes population) and can also be used by anyone on
insulin pump therapy. They are also the only CGM systems with
accuracy approved for the user to make diabetes treatment decisions
(such as insulin dosing) without the need for a fingerstick*.
With both Dexcom G5 & G6 CGM Systems, a Sensor is inserted
under the skin to measure the level of glucose in the interstitial
fluid (fluid in the tissue). A Transmitter is attached to the
Sensor, sending glucose readings continuously to a Receiver or
compatible smart device†. The life of the Transmitter is 90
days, so any Dexcom G5 user is only ever 90 days away from the
latest generation of technology, once it becomes available.
About CGM
CGM devices are considered the most
significant breakthrough in diabetes management in the past 40
years1 and Dexcom has been a leader in bringing
such innovations to patients with diabetes. Type 1 diabetes affects
nearly 300,000 Canadians2. The traditional
standard for glucose monitoring has been a blood glucose meter,
requiring the user to perform painful fingersticks each time they
wish to get a reading. CGM not only diminishes the burden of
routine fingersticks, but beyond just getting a glucose level
number, CGM also provides the direction and rate of glucose change
at a glance - and alerts users when glucose levels are too low or
too high. This is especially significant at night. People with
diabetes who take insulin must monitor their glucose levels
frequently. Uncontrolled glucose can cause health complications and
even
death3,4. To
learn more about CGM, visit www.dexcom.com.
About DexCom, Inc.
DexCom, Inc. is headquartered
in San Diego, CA, and has operations in Canada. It
is dedicated to helping people better manage their diabetes by
developing and marketing continuous glucose monitoring (CGM)
products and tools for adult and pediatric patients.
*With Dexcom G5
Mobile and Dexcom G6, you should perform a fingerstick to confirm
your blood glucose level if your glucose alerts and readings do not
match your symptoms or expectations. With Dexcom G5 Mobile,
you should also confirm your glucose level if you are taking
medications containing acetaminophen, and two fingersticks a day
are required for calibration.
|
†To view a list of
compatible devices, visit www.dexcom.com/compatibility
|
ǂ Following requires
the Dexcom Follow app and an internet connection.
|
|
1 Clarke
SF and Foster JR. A history of blood glucose meters and their role
in self-monitoring of diabetes mellitus. Br J Biomed Sci.
2012;(3)2:83-93.
|
2 Canadian
Diabetes Association. The prevalence and costs of diabetes.
December 2009.
|
3
Hyperglycemia (High blood glucose). American Diabetes Association
Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.
Updated August 5, 2013. Accessed December 3, 2013.
|
4
Hypoglycemia (Low blood glucose). American Diabetes Association Web
site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.
Updated July 16, 2013. Accessed December 3, 2013.
|
SOURCE Dexcom, Inc.